Jan 14, 2025 · “FTC staff have found that the Big 3 PBMs are charging enormous markups on dozens of lifesaving drugs,” said Hannah Garden-Monheit, Director of the FTC’s Office of Policy Planning. “We also found that this problem is growing at an alarming rate, which means there is an urgent need for policymakers to address it.”

The Federal Trade Commission today published an interim report on the prescription drug middleman industry that underscores the impact pharmacy benefit managers (PBMs) have on the accessibility and affordability of prescription drugs.

The FTC issues this staffreport in connection with our ongoing study of the PBM industry. In June 2022, the FTC issued special orders pursuant to Section 6(b) of the Federal Trade Commission Act to the six largest PBMs (the “PBM respondents” or “respondents”), including . the Big 3 PBMs (the “6(b) Orders”). 24

Jan 14, 2025 · The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through...

Sep 21, 2024 · In a new lawsuit filed Friday, the Federal Trade Commission said it's going after one link in the chain: pharmacy benefit managers (PBMs). The FTC brought action against the top PBMs — CVS ...

Jul 20, 2024 · Now, PBMs are center stage for the FTC. The Federal Trade Commission has turned its attention to these powerful intermediaries and is, according to the Wall Street Journal, considering a lawsuit...

Jul 9, 2024 · PBMs, which serve as middlemen in the drug supply chain by negotiating rebates with drug manufacturers on behalf of insurers, large employers and others, could be steering patients to their own...

Jan 14, 2025 · However, the FTC’s first report from its investigation was highly critical of PBMs, finding unchecked consolidation has resulted in a few major players wielding outsized influence to profit at ...

Jan 22, 2025 · At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report (Second Report) stemming from its investigation into pharmacy benefit managers (PBMs) and their impacts on competition in the health care marketplace. The Second Report, released following a unanimous vote of the commissioners, expands on aContinue Reading

Jan 15, 2025 · The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers” as part of an ongoing study examining the practices of Pharmacy Benefit Managers (PBMs) within the U.S. healthcare system. This report highlights significant concerns about the pricing strategies of PBMs concerning ...